edison tv
Investment Companies
“Edison is the go-to for a new investor to get full understanding of the investment case and business. Edison’s distribution reaches investors that we want to connect with directly.”
Associated equity: Context Therapeutics
Context Therapeutics — 4 videos in collection
Context Therapeutics (Nasdaq: CNTX) is a biopharmaceutical company committed to advancing medicines for solid tumors. Context is developing CTIM-76, a selective Claudin 6 (CLDN6) x CD3 bispecific antibody for CLDN6-positive tumors, currently in preclinical development.
The company’s CEO, Martin Lehr, scientific lead Dr Eric Butz and research lead Dr Joseph Rucker will discuss Context’s CLDN6 x CD3 bispecific antibody’s American Association for Cancer Research 2023 presentation and provide preclinical program updates on this potential treatment for multiple solid tumors including ovarian, lung and testicular cancers.
Get access to the very latest content matched to your personal investment style.